Win For AZ's COPD Triple Combo In Bid To Catch GSK

 
• By Kevin Grogan

GlaxoSmithKline is streets ahead in the three-in-one COPD market, having received approval last year in the USA and Europe for Trelegy Ellipta, but AstraZeneca's PT010 may provide competition in the future having met six out of seven lung function primary endpoints in a Phase III trial.

Skydivers
AstraZeneca has positive Phase III data on its COPD triple combination • Source: Shutterstock

More from Clinical Trials

More from R&D